Synopsis
Plan interruption and resumption of antithrombotic treatment around the actual operation, preserving protection against thrombosis while avoiding preventable surgical or neuraxial bleeding.
- Establish the medicine, indication, dose and exact last administration before choosing an interruption plan.
- Bleeding risk depends on both the procedure and the consequences of bleeding in that anatomical space.
- Use an appropriate renal assessment and identify recent VTE, coronary stents and other high-risk indications.
Key red flags
Stopping antiplatelet treatment soon after coronary intervention can expose the patient to serious arterial thrombosis. Establish the intervention date, clinical indication and intended antiplatelet course, then involve cardiology and the procedural team. Routine cancellation of every antiplatelet prescription is not a safe substitute for that assessment.
Identify the exact last dose and current physiology, and obtain senior anaesthetic, surgical and haematology advice. A normal PT or aPTT cannot reassure the team that apixaban has no effect. The urgency of intervention and availability of informative drug testing influence the plan.
A patient restarted on apixaban may still have postoperative LMWH charted. Unless a specialist-defined exception applies, concurrent anticoagulants increase bleeding risk. Reconcile the stop and start orders explicitly and explain the transition to the patient and nursing team.
Reasoning priorities
Determine what the patient has taken and what it is intended to prevent.
Use the patient, prescription record and relevant specialist letters. Ask about missed or extra doses and the exact timing of the last administration. The medication list can remain unchanged while the patient has already followed a separate preoperative instruction.
Worked reasoning
A 68-year-old with non-valvular atrial fibrillation takes apixaban 5 mg at 08:00 and 20:00. Weight is 84 kg and creatinine clearance 80 mL/min. There has been no recent VTE. Elective high-bleeding-risk abdominal surgery is planned for Friday morning without neuraxial anaesthesia; the team adopts the UKCPA five-omitted-dose schedule.
- Confirm that the stated regular dose and clinical factors fit the planned pathway. Clarify the procedure’s bleeding risk with the operator and confirm that no epidural or spinal technique has been added. The example does not authorise the same schedule for a different patient with severe renal impairment.
- Translate the schedule into clock times. The final dose is Tuesday at 20:00. Omit both Wednesday doses, both Thursday doses and the Friday morning dose: five doses omitted, with roughly sixty hours between the last dose and a Friday 08:00 procedure.
- Do not add routine therapeutic-dose LMWH bridging for this apixaban interruption. If postoperative pharmacological VTE prevention is indicated while full anticoagulation remains unsafe, that is a separate prophylactic plan based on haemostasis and surgical risk.
- Write a provisional restart review for forty-eight to seventy-two hours after high-risk surgery under the UKCPA approach, with actual administration dependent on secure haemostasis, oral absorption and the postoperative course. A timestamp alone must not force a dose during active bleeding or ileus.
- At restart, reconcile the chart so any temporary LMWH is stopped and the correct oral dose resumes without duplication. Ask the patient to repeat which tablets to omit and when the team will confirm restarting; verify the final plan again if the operation is rescheduled.